首页> 外文期刊>Expert Review of Molecular Diagnostics >Selecting analytical biomarkers for diagnostic applications: a first principles approach
【24h】

Selecting analytical biomarkers for diagnostic applications: a first principles approach

机译:选择分析生物标志物进行诊断应用:第一个原则方法

获取原文
获取原文并翻译 | 示例
           

摘要

Introduction: Biomarkers are objective indications of a medical state that can be measured accurately and reproducibly. Traditional biomarkers enable diagnosis of disease through detection of disease-specific molecules, disease-mediated molecular changes, or distinct physiological or anatomical signatures. Areas covered: This work provides a framework for selecting biomarkers that are most likely to provide useful information about a patients disease state. Though the authors emphasize markers related to disease, this work is also applicable to biomarkers for monitoring physiological changes such as ovulation or pregnancy. Additionally, the scope was restricted to biomarkers that are amenable to analytical detection across a range of health care levels, including low resource settings. The authors describe trade-offs between biomarkers sensitivity/specificity for a disease-causing agent, the complexity of detection, and how this knowledge can be applied to the development of diagnostic tests. This report also details additional assessment criteria for successful tests. Expert commentary: Biomarker selection should primarily be driven by an attempt to answer an explicit clinical question (preferably causative relationship of the biomarker to disease-state), and only then by test development expediency (ease of detection). This framework is useful for stakeholders from test developers to clinicians to identify the trade-offs for diagnostic biomarkers for any use case. ?2017 Informa UK Limited, trading as Taylor & Francis Group.
机译:简介:生物标志物是可以准确且可重复测量的医学状态的客观指示。传统生物标志物通过检测疾病特异性分子,疾病介导的分子变化或不同的生理或解剖签名来实现疾病的诊断。所涵盖的地区:这项工作为选择最有可能提供有关患者疾病状态的有用信息的生物标志物提供框架。虽然作者强调了与疾病相关的标志物,但这项工作也适用于生物标志物,用于监测排卵或怀孕等生理变化。此外,该范围仅限于跨一系列医疗保健水平的分析检测的生物标志物,包括低资源设置。作者描述了生物标志物敏感性/特异性对疾病引发剂的特异性的权衡,检测的复杂性以及如何应用于诊断测试的发展。本报告还详细介绍了成功测试的其他评估标准。专家评论:生物标志物选择应该主要由试图回答明确的临床问题(优选致病态的致病状态的致病关系)的驱动,并且仅通过测试发展权限(易于检测)。此框架对于从测试开发人员到临床医生的利益相关者是有用的,以确定任何用例的诊断生物标志物的权衡。 ?2017年Informa UK Limited,贸易为泰勒和弗朗西斯集团。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号